DWTX Seeks Shareholder Nod for Preferred Stock Conversion, Equity Plan

TL;DR

**DWTX needs these approvals to unlock value from its acquisitions and fuel growth; vote FOR or risk stagnation.**

AI Summary

Dogwood Therapeutics, Inc. (DWTX) is holding a Special Meeting on November 21, 2025, to seek stockholder approval for several key proposals related to its recent acquisitions of Halneuron and SP16 technologies. The company needs approval for the potential issuance of common stock upon conversion of its Series A, Series A-1, and Series A-2 Non-Voting Convertible Preferred Stock, as required by Nasdaq Listing Rule 5635. These conversions are crucial to reflect the economic contribution of the acquired technologies and increase DWTX's common stock capitalization, which the Board believes will enhance research programs and strategic development. Additionally, stockholders will vote on the approval of the Dogwood Therapeutics, Inc. Second Amended and Restated 2020 Equity Incentive Plan and the potential adjournment of the meeting. The Board of Directors unanimously recommends a 'FOR' vote on all proposals, emphasizing the importance of these actions for the company's future growth and investor confidence, particularly with its late-stage Halneuron, a first-in-class Na v 1.7 inhibitor with FDA fast-track review for chemotherapy-induced neuropathic pain.

Why It Matters

This DEF 14A filing is critical for DWTX investors as it outlines proposals to convert significant preferred stock holdings into common stock, potentially diluting existing shareholders but also reflecting the value of recent technology acquisitions like Halneuron and SP16. Approval of these conversions and the new equity incentive plan could signal confidence from major investors and enable DWTX to expand its R&D, particularly for its FDA fast-track designated Halneuron. Failure to approve could hinder DWTX's ability to fully integrate its acquisitions and attract future capital, impacting its competitive position in the pain and neuropathy research market against larger pharmaceutical players.

Risk Assessment

Risk Level: medium — The risk level is medium due to potential dilution from the conversion of Series A, A-1, and A-2 Preferred Stock into common stock, which could impact existing shareholders. Additionally, Nasdaq listing rules require specific exclusions for voting on Proposals 1 and 3 (211,951 shares and 382,034 shares respectively), indicating a complex voting structure that could lead to unexpected outcomes if not carefully managed, potentially delaying strategic initiatives.

Analyst Insight

Investors should carefully review the potential dilution impact of the preferred stock conversions on their holdings. Given the Board's unanimous recommendation and the strategic importance of these approvals for DWTX's R&D and capitalization, voting 'FOR' all proposals aligns with supporting the company's stated growth trajectory and leveraging its acquired technologies.

Key Numbers

• 2,293,162 — Common Stock Shares Outstanding (As of the Record Date, each share has one vote.)
• 2,269.1494 — Series A Preferred Stock Shares (Outstanding, non-voting, subject to conversion approval.)
• 284.2638 — Series A-1 Preferred Stock Shares (Outstanding, non-voting, subject to conversion approval.)
• 190.0572 — Series A-2 Preferred Stock Shares (Outstanding, non-voting, subject to conversion approval.)
• 211,951 — Common Stock Shares Excluded from Proposal 1 Vote (Not entitled to vote on Proposal No. 1 per Nasdaq rules.)
• 382,034 — Common Stock Shares Excluded from Proposal 3 Vote (Not entitled to vote on Proposal No. 3 per Nasdaq rules.)
• November 21, 2025 — Special Meeting Date (Date when stockholders will vote on the proposals.)
• 10:00 a.m. — Special Meeting Time (Eastern Time, for the virtual meeting.)
• October 20, 2025 — Proxy Materials Mailing Date (Date proxy materials were mailed to stockholders.)

Key Players & Entities

• Dogwood Therapeutics, Inc. (company) — Registrant and company seeking approvals
• DWTX (company) — Ticker symbol for Dogwood Therapeutics, Inc.
• Nasdaq Listing Rule 5635 (regulator) — Rule requiring stockholder approval for stock issuance
• Halneuron (company) — Acquired technology, first-in-class Na v 1.7 inhibitor
• SP16 (company) — Acquired technology
• Greg Duncan (person) — Chairman and Chief Executive Officer of Dogwood Therapeutics, Inc.
• Angela Walsh (person) — Proxy appointed by the Board of Directors
• $0.0001 (dollar_amount) — Par value per share for Common Stock and Preferred Stock
• 2,293,162 (dollar_amount) — Shares of Common Stock outstanding as of Record Date
• October 14, 2025 (date) — Record Date for voting eligibility

FAQ

Risk Factors

• Nasdaq Listing Rule Compliance [high — regulatory]: The company requires stockholder approval to issue common stock upon conversion of preferred stock to comply with Nasdaq Listing Rule 5635. Failure to obtain approval could prevent the company from increasing its common stock capitalization, impacting its ability to reflect the economic contribution of acquired technologies and fund research programs.
• Dependence on Key Drug Development [high — market]: The company's future success is heavily reliant on the development and commercialization of its late-stage Halneuron program, a Na v 1.7 inhibitor for chemotherapy-induced neuropathic pain. The FDA's fast-track review designation is positive, but regulatory hurdles and market acceptance remain significant risks.
• Integration of Acquired Technologies [medium — operational]: The company has recently acquired Halneuron and SP16 technologies. The successful integration and exploitation of these technologies are critical for future growth. Any operational challenges or delays in leveraging these acquisitions could negatively impact the company's performance.
• Capitalization and Funding Needs [medium — financial]: The proposed stock issuance aims to increase common stock capitalization to support research and development. The company's ability to secure future funding, especially if these proposals are not approved, is crucial for its ongoing operations and development pipeline.

Industry Context

Dogwood Therapeutics operates in the biopharmaceutical sector, focusing on developing treatments for pain and neuropathy. The company's lead candidate, Halneuron, targets chemotherapy-induced neuropathic pain, a significant unmet medical need. The industry is characterized by high R&D costs, long development cycles, and stringent regulatory oversight from bodies like the FDA. Success hinges on clinical trial outcomes, regulatory approvals, and market adoption, with competition from both established pharmaceutical giants and emerging biotech firms.

Regulatory Implications

The primary regulatory implication for Dogwood Therapeutics at this juncture is the need for stockholder approval under Nasdaq Listing Rule 5635 to issue common stock upon preferred stock conversion. Failure to secure this approval could impede the company's ability to increase its equity capitalization as planned. Additionally, the company's Halneuron program is subject to the rigorous FDA review process, with its fast-track designation indicating a potentially expedited but still demanding path to market approval.

What Investors Should Do

1. Vote 'FOR' Proposal 1, 2, and 3: Approve the potential issuance of common stock upon conversion of Series A, A-1, and A-2 Preferred Stock to comply with Nasdaq rules and increase equity capitalization, supporting research and development.
2. Vote 'FOR' Proposal 4: Approve the Dogwood Therapeutics, Inc. Second Amended and Restated 2020 Equity Incentive Plan to ensure the company can continue to attract and retain talent by offering equity-based compensation.
3. Vote 'FOR' Proposal 5: Approve the adjournment of the Special Meeting if necessary, providing flexibility to ensure all necessary approvals are obtained.
4. Review the Proxy Statement carefully to understand the implications of each proposal on share dilution and future company strategy.

Key Dates

• 2025-10-14: Record Date — Establishes the stockholders eligible to vote at the Special Meeting.
• 2025-10-20: Proxy Materials Mailing Date — Date when stockholders received the proxy statement and voting instructions, initiating the solicitation period.
• 2025-11-21: Special Meeting Date — The date for stockholders to vote on critical proposals, including stock issuance and equity plan approval.

Glossary

DEF 14A

A filing with the U.S. Securities and Exchange Commission (SEC) that provides detailed information to shareholders in preparation for an annual or special meeting of stockholders. (This document is the proxy statement for Dogwood Therapeutics' special meeting, outlining the proposals and information necessary for stockholders to make informed voting decisions.)

Nasdaq Listing Rule 5635

A rule set by Nasdaq that requires stockholder approval for certain issuances of stock, typically when the issuance exceeds 20% of the outstanding common stock or involves the sale of stock at a price below the market price. (Dogwood Therapeutics needs stockholder approval under this rule to issue common stock upon conversion of preferred stock, which is a key purpose of the special meeting.)

Non-Voting Convertible Preferred Stock

A class of stock that has preference over common stock in dividends and asset distribution but does not carry voting rights. It can be converted into a predetermined number of common stock shares. (Dogwood Therapeutics has Series A, A-1, and A-2 Non-Voting Convertible Preferred Stock outstanding, the conversion of which into common stock requires stockholder approval.)

FDA Fast-Track Review Designation

A designation granted by the U.S. Food and Drug Administration (FDA) to expedite the development and review of drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. (The Halneuron program has received this designation, indicating potential for accelerated development and approval for treating chemotherapy-induced neuropathic pain.)

Equity Incentive Plan

A plan established by a company to grant stock options, restricted stock units, or other equity-based awards to employees, directors, and consultants as a form of compensation and to align their interests with those of shareholders. (Stockholders are being asked to approve the Dogwood Therapeutics, Inc. Second Amended and Restated 2020 Equity Incentive Plan, which is a standard practice for companies to incentivize and retain key personnel.)

Year-Over-Year Comparison

This filing is for a Special Meeting and focuses on specific proposals related to recent acquisitions and equity structure adjustments, rather than a comprehensive annual review. Therefore, direct year-over-year comparisons of financial metrics like revenue growth or net income are not applicable to this specific DEF 14A. The key focus is on enabling future growth through strategic stock issuance and equity plan approval, driven by the acquisition of promising technologies like Halneuron.

Key Financial Figures

• $0.0001 — Convertible Preferred Stock, par value $0.0001 per share; (2) Approval, for the purpo

Filing Documents

• dwtx-20251121xdef14a.htm (DEF 14A) — 949KB
• dwtx-20251121xdef14a_a001.jpg (GRAPHIC) — 5KB
• dwtx-20251121xdef14a_bg001.jpg (GRAPHIC) — 110KB
• dwtx-20251121xdef14a_bg002.jpg (GRAPHIC) — 124KB
• 0001104659-25-100850.txt ( ) — 1279KB

From the Filing

DEF 14A 1 dwtx-20251121xdef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 DOGWOOD THERAPEUTICS, INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. Table of Contents 44 Milton Avenue Alpharetta, GA 30009 NOTICE OF SPECIAL MEETING OF STOCKHOLDERS To Be Held on November 21, 2025 October 20, 2025 To our Stockholders: You are cordially invited to attend the special meeting of stockholders (the "Special Meeting") of Dogwood Therapeutics, Inc. (the "Company," "we" or "our"), which will be held on Friday, November 21, 2025, at 10:00 a.m., Eastern Time. The Special Meeting will be conducted as a completely virtual meeting of stockholders. You can attend the Special Meeting by visiting https://edge.media-server.com/mmc/go/DWTX2025SGM where you will be able to listen to the Special Meeting live, submit questions, view the stockholder list and vote online. Because the Special Meeting is completely virtual and being conducted via the Internet, stockholders will not be able to attend the Special Meeting in person physically. Only stockholders who held the Company's stock at the close of business on the record date, October 14, 2025, may vote at the Special Meeting, including any adjournment or postponement thereof. At the Special Meeting, you will be asked to consider and vote upon: (1) Approval, for the purposes of complying with the applicable provisions of Nasdaq Listing Rule 5635, the potential issuance of our common stock upon conversion of the Company's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share; (2) Approval, for the purposes of complying with the applicable provisions of Nasdaq Listing Rule 5635, the potential issuance of our common stock upon conversion of the Company's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share; (3) Approval, for the purposes of complying with the applicable provisions of Nasdaq Listing Rule 5635, the potential issuance of our common stock upon conversion of the Company's Series A-2 Non-Voting Convertible Preferred Stock, par value $0.0001 per share; (4) Approval of the Dogwood Therapeutics, Inc. Second Amended and Restated 2020 Equity Incentive Plan; (5) Approval of the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate; and (6) the transaction of any other business that may properly come before the Special Meeting or any adjournment thereof. Pursuant to our bylaws, no other items of business are expected to be considered at the Special Meeting. As you have seen in our prior public statements, in the last year we have engaged in two transactions in which we acquired two exciting technologies – Halneuron and SP16 – that we are now seeking to exploit. In both transactions, we issued shares of common stock and shares of non-voting convertible preferred stock. Under applicable Nasdaq rules, the potential conversion of the preferred stock into common stock is subject to stockholder approval. The board of directors and I believe conversion of existing Dogwood Therapeutics, Inc. preferred stock into common stock and the associated Table of Contents increase in the Company's common stock capitalization are in the best interest of the Company and will better reflect the economic contribution of these technologies to the Company as well as the inherent value of our pain and neuropathy research programs, notably including our late stage Halneuron , a first-in-class Na v 1.7 inhibitor which has been granted FDA fast-track review designation to treat chemotherapy induced neuropathic pain. We believe an increase in Dogwood Therapeutics, Inc.'s capitalization, underpinned by several significant investors with deep experience in our industry, enhances our ability to continue and expand the breadth of our research programs, business and partnership development and other strategic considerations moving forward. The accompanying Proxy Statement more fully describes the details of the business to be conducted at the Special Meeting. After careful consideration, our Board of Directors has unanimously approved and recommends that you vote "FOR" each of th

View Full Filing

View this DEF 14A filing on SEC EDGAR